The Science, The Promise, and The Questions We Can’t Ignore
In early April, a study published in Science Advances revealed something that feels like it’s been pulled straight from science fiction.
Researchers successfully reprogrammed a tobacco plant to produce five different psychedelic compounds at once — including DMT, psilocybin, and 5-MeO-DMT.
Not separately. Not in different systems.
All within a single leaf.
At OnlySpores, we’ve seen a lot of innovation in the mycology and research space. But this? This is a genuine leap forward — and one that raises just as many questions as it answers.
Let’s break down what’s actually going on here.
What Did They Actually Do?
At its core, this study is about synthetic biology — the ability to take genetic instructions from one organism and run them inside another.
In this case, scientists took biosynthetic genes from:
- A plant (for DMT)
- A mushroom (for psilocybin)
- A toad (for 5-MeO-DMT)
…and inserted them into a species of tobacco called Nicotiana benthamiana.
The result?
A single plant capable of producing:
- N,N-DMT
- 5-MeO-DMT
- Bufotenin
- Psilocybin
- Psilocin
This is what’s known as a heterologous production system — essentially turning one organism into a biological factory for compounds it never evolved to produce.
Why Tobacco?
It sounds random, but it’s actually very deliberate.
Nicotiana benthamiana is the botanical equivalent of a lab mouse. It’s widely used in research because:
- It grows quickly
- It’s easy to genetically modify
- It tolerates foreign DNA extremely well
But more importantly, it naturally produces tryptophan — the amino acid that sits at the root of many psychedelic compounds.
That makes it the perfect starting point.
How The Psychedelics Were Built
1. The DMT Pathway (From Plants)
The team sourced genes from Psychotria viridis — a plant traditionally used in ayahuasca.
The pathway is surprisingly simple:
- Tryptophan → Tryptamine → NMT → DMT
By inserting just a couple of genes, the tobacco plant was able to complete this pathway on its own.
2. The Psilocybin Pathway (From Mushrooms)
For psilocybin, researchers turned to Psilocybe cubensis.
This pathway is more complex and includes a phosphorylation step — something plants don’t typically do in this context.
Importing the full enzyme system from a mushroom into a plant is no small feat.
It’s one of the first times this has been successfully demonstrated.
3. The 5-MeO-DMT Pathway (From Toads)
This is where things get particularly wild.
Genes were sourced from the Rhinella marina — a relative of the Sonoran Desert toad, known for producing 5-MeO-DMT.
To make this work, scientists had to:
- Combine enzymes from multiple species
- Engineer new pathways that don’t naturally exist in plants
- Use AI tools like AlphaFold to optimise enzyme performance
At one point, a single amino acid tweak increased output 30-fold.
That’s the level of precision we’re now working with.
So… Why Does This Matter?
It’s easy to look at this and think: “Cool, but why?”
The answer is actually very practical.
Psychedelics Have a Supply Problem
As research into psychedelic-assisted therapies accelerates, demand for these compounds is rising fast.
But sourcing them isn’t always straightforward:
- Psilocybin — relatively easy to cultivate
- DMT — extractable from plants like Mimosa tenuiflora
- 5-MeO-DMT — often sourced from toads (not scalable, not ethical)
This is where engineered plants come in.
They offer a way to:
- Produce compounds sustainably
- Reduce pressure on wild ecosystems
- Scale production for research and clinical use
- Create entirely new compounds for study
No toads. No overharvesting. No fragile supply chains.
Should We Be Concerned?
Here’s where things get more nuanced.
The technique used — agroinfiltration — relies on a bacterium called Agrobacterium tumefaciens to temporarily insert genes into plant cells.
Crucially:
- These changes are not permanent
- They are not passed to future generations
- Each plant is produced in controlled lab conditions
So right now, there’s no risk of “psychedelic tobacco” spreading in the wild.
But the door has been opened.
And if future work makes these changes stable and heritable?
That’s when the conversation shifts from science to ethics.
The Bigger Picture
This research doesn’t just replicate known psychedelics.
It also enables the creation of new-to-nature compounds — molecules that have never existed before.
If you’re familiar with the work of Alexander Shulgin, you’ll know that even small tweaks to a molecule can dramatically change its effects.
We’re now entering a phase where:
- New compounds can be designed
- Produced biologically
- Tested more efficiently
That’s a massive shift.
OnlySpores Take
This is one of the most significant developments in psychedelic research we’ve seen in years.
It solves real-world problems:
- Sustainability
- Scalability
- Accessibility
But it also raises bigger questions about where this technology leads.
Because history tells us something important:
Breakthroughs like this rarely stay contained.
They evolve.
They scale.
They move faster than regulation can keep up.
The science here is exceptional.
What comes next depends entirely on how it’s used.
Final Thoughts
We’re watching the boundaries between biology, chemistry, and technology blur in real time.
A tobacco plant producing psychedelics might sound surreal — but it’s now a proven reality.
And while this opens the door to better medicine, better research, and more sustainable practices…
…it also reminds us that just because we can engineer nature, doesn’t always answer whether we should.
Source: Only Spores
Image created via ChatGPT sent with permissions from Only Spores
